Henlez is advancing a pre-clinical program called HEN-001, an enzyme-based topical application intended to treat hidradenitis suppurativa. The company is developing HEN-001 to address a chronic, stigmatizing inflammatory skin condition characterized by severe pain, malodorous drainage and scarring. Henlez plans to use recent funding to further develop the topical candidate and facilitate a forthcoming clinical evaluation. The company also intends to expand its patent portfolio with the proceeds. Henlez was founded in 2019 by Jeppe Mouritsen, a former Novozymes A/S scientist who serves as CEO. The startup is described in the article as Danish.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2022